GDNF gene therapy - Aventis Gencell

Drug Profile

GDNF gene therapy - Aventis Gencell

Alternative Names: Glial cell line-derived neurotrophic factor gene therapy - Aventis Gencell; Parkinson's disease gene therapy - Aventis Gencell

Latest Information Update: 04 Jul 2002

Price : $50

At a glance

  • Originator Aventis Gencell; CNRS
  • Class Antiparkinsonians; Gene therapies; Neuroprotectants
  • Mechanism of Action Glial cell line-derived neurotrophic factor expression stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Parkinson's disease

Most Recent Events

  • 24 Dec 1999 Rhône-Poulenc Rorer Gencell is now Aventis Gencell
  • 02 Dec 1997 Preclinical development for Parkinson's disease in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top